Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria.
Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder.
Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 31, 24 | -2.42 Decreased by -47.56% | 1.11 Decreased by -318.02% |
| Aug 1, 24 | -1.69 Decreased by -11.92% | -1.60 Decreased by -5.62% |
| May 2, 24 | -1.45 Increased by +1.36% | -1.65 Increased by +12.12% |
| Feb 15, 24 | -1.72 Decreased by -356.72% | -1.65 Decreased by -4.24% |
| Nov 2, 23 | -1.64 Decreased by -10.07% | -1.70 Increased by +3.53% |
| Aug 3, 23 | -1.51 Increased by +10.12% | -1.56 Increased by +3.21% |
| May 4, 23 | -1.47 Increased by +15.52% | -1.70 Increased by +13.53% |
| Feb 23, 23 | 0.67 Increased by +138.51% | -1.62 Increased by +141.36% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 8.96 M Increased by +21.15% | 947.91 M Increased by +1.14 K% | Increased by +10.57 K% Increased by +956.75% |
| Jun 30, 24 | 8.62 M Increased by +28.35% | -96.12 M Decreased by -14.69% | Decreased by -1.12 K% Increased by +10.64% |
| Mar 31, 24 | 8.19 M Increased by +46.00% | -81.55 M Decreased by -14.18% | Decreased by -995.84% Increased by +21.79% |
| Dec 31, 23 | 7.10 M Increased by +64.80% | -95.94 M Decreased by -155.71% | Decreased by -1.35 K% Decreased by -133.80% |
| Sep 30, 23 | 7.40 M Increased by +110.44% | -91.32 M Decreased by -26.13% | Decreased by -1.23 K% Increased by +40.06% |
| Jun 30, 23 | 6.71 M Increased by +20.24% | -83.81 M Increased by +2.52% | Decreased by -1.25 K% Increased by +18.93% |
| Mar 31, 23 | 5.61 M Increased by +574.16% | -71.42 M Increased by +19.21% | Decreased by -1.27 K% Increased by +88.02% |
| Dec 31, 22 | 4.31 M Increased by +10.41 M% | 172.22 M Increased by +282.00% | Increased by +4.00 K% Increased by +100.00% |